company background image
ACBM

Acro Biomedical OTCPK:ACBM Stock Report

Last Price

US$4.48

Market Cap

US$269.0m

7D

12.3%

1Y

5.4%

Updated

13 Aug, 2022

Data

Company Financials
ACBM fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

ACBM Stock Overview

Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products.

Acro Biomedical Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Acro Biomedical
Historical stock prices
Current Share PriceUS$4.48
52 Week HighUS$5.00
52 Week LowUS$2.03
Beta1.16
1 Month Change11.72%
3 Month Change12.00%
1 Year Change5.41%
3 Year Change-10.40%
5 Year Changen/a
Change since IPO79.20%

Recent News & Updates

Shareholder Returns

ACBMUS HealthcareUS Market
7D12.3%2.3%3.2%
1Y5.4%14.7%-10.2%

Return vs Industry: ACBM underperformed the US Healthcare industry which returned 17.7% over the past year.

Return vs Market: ACBM exceeded the US Market which returned -10.1% over the past year.

Price Volatility

Is ACBM's price volatile compared to industry and market?
ACBM volatility
ACBM Average Weekly Movementn/a
Healthcare Industry Average Movement8.8%
Market Average Movement7.7%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.2%

Stable Share Price: Insufficient data to determine ACBM's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine ACBM's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014n/aRichard Chuhttps://acrobiomedicalco.com

Acro Biomedical Co., Ltd. engages in developing and marketing of nutritional products. It sells cordycepin and cordyceps powder, a fungus used in traditional Chinese medicine. The company was formerly known as Killer Waves Hawaii, Inc. and changed its name to Acro Biomedical Co., Ltd.

Acro Biomedical Fundamentals Summary

How do Acro Biomedical's earnings and revenue compare to its market cap?
ACBM fundamental statistics
Market CapUS$268.99m
Earnings (TTM)-US$14.77m
Revenue (TTM)US$896.50k

300.1x

P/S Ratio

-18.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ACBM income statement (TTM)
RevenueUS$896.50k
Cost of RevenueUS$670.00k
Gross ProfitUS$226.50k
Other ExpensesUS$15.00m
Earnings-US$14.77m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.25
Gross Margin25.26%
Net Profit Margin-1,647.42%
Debt/Equity Ratio3.7%

How did ACBM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ACBM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACBM?

Other financial metrics that can be useful for relative valuation.

ACBM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue300.1x
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does ACBM's PB Ratio compare to its peers?

ACBM PB Ratio vs Peers
The above table shows the PB ratio for ACBM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average31.5x
AATP Agape ATP
119.8xn/aUS$302.6m
PETQ PetIQ
1.6xn/aUS$438.7m
GEG Great Elm Group
1.7xn/aUS$59.9m
OMI Owens & Minor
2.8x21.2%US$2.7b
ACBM Acro Biomedical
468.1xn/aUS$269.0m

Price-To-Book vs Peers: ACBM is expensive based on its Price-To-Book Ratio (468.1x) compared to the peer average (31.5x).


Price to Earnings Ratio vs Industry

How does ACBM's PE Ratio compare vs other companies in the US Healthcare Industry?

Price-To-Book vs Industry: ACBM is expensive based on its Price-To-Book Ratio (468.1x) compared to the US Healthcare industry average (2.7x)


Price to Book Ratio vs Fair Ratio

What is ACBM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACBM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio468.1x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ACBM's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ACBM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ACBM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ACBM's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Acro Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


12.9%

Forecasted Healthcare industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Acro Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Acro Biomedical's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Acro Biomedical's filings and announcements here.

Past Performance

How has Acro Biomedical performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-92.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ACBM is currently unprofitable.

Growing Profit Margin: ACBM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ACBM is unprofitable, and losses have increased over the past 5 years at a rate of 92.4% per year.

Accelerating Growth: Unable to compare ACBM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACBM is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8.1%).


Return on Equity

High ROE: ACBM has a negative Return on Equity (-2569.04%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Acro Biomedical's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ACBM's short term assets ($626.9K) exceed its short term liabilities ($81.5K).

Long Term Liabilities: ACBM's short term assets ($626.9K) exceed its long term liabilities ($13.0K).


Debt to Equity History and Analysis

Debt Level: ACBM's net debt to equity ratio (1.6%) is considered satisfactory.

Reducing Debt: ACBM had negative shareholder equity 5 years ago, but is now positive and has therefore improved.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ACBM has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ACBM has less than a year of cash runway if free cash flow continues to grow at historical rates of 32.1% each year.


Discover healthy companies

Dividend

What is Acro Biomedical current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ACBM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ACBM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ACBM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ACBM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ACBM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Richard Chu (68 yo)

5.58yrs

Tenure

Mr. Pao-Chi Chu, also known as Richard, has been Chief Executive Officer, President, Chief Financial Officer, Secretary and Director of Acro Biomedical Co., Ltd. since January 30, 2017 and serves as its Ch...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.1%.


Top Shareholders

Company Information

Acro Biomedical Co., Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Acro Biomedical Co., Ltd.
  • Ticker: ACBM
  • Exchange: OTCPK
  • Founded: 2014
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Implied Market Cap: US$268.988m
  • Shares outstanding: 60.04m
  • Website: https://acrobiomedicalco.com

Location

  • Acro Biomedical Co., Ltd.
  • 12175 Visionary Way
  • Suite 1160
  • Fishers
  • Indiana
  • 46038
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/13 00:00
End of Day Share Price2022/08/11 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.